Antisense inhibition of urokinase reduces spread of human ovarian cancer in mice

[1]  H. Höfler,et al.  Urokinase (uPA) and its inhibitor PAI-1 are strong and independent prognostic factors in node-negative breast cancer , 2005, Breast Cancer Research and Treatment.

[2]  P. Dettmar,et al.  Urokinase (uPA) and PAI-1 predict survival in advanced ovarian cancer patients (FIGO III) after radical surgery and platinum-based chemotherapy. , 1994, Gynecologic oncology.

[3]  R. Kreienberg,et al.  Expression of urokinase-type plasminogen-activator (upa) and its receptor (upar) in human ovarian-cancer cells and in-vitro invasion capacity. , 1994, International journal of oncology.

[4]  Y. Kook,et al.  The effect of antisense inhibition of urokinase receptor in human squamous cell carcinoma on malignancy. , 1994, The EMBO journal.

[5]  H. Kobayashi,et al.  Inhibition of the Metastasis of Lewis Lung Carcinoma by Antibody Against Urokinase-Type Plasminogen Activator in the Experimental and Spontaneous Metastasis Model , 1994, Thrombosis and Haemostasis.

[6]  P. Carmeliet,et al.  Physiological consequences of loss of plasminogen activator gene function in mice , 1994, Nature.

[7]  S. Hoehl,et al.  The urokinase/urokinase receptor system A new target for cancer therapy? , 1994 .

[8]  U. Weidle,et al.  Recombinant soluble urokinase receptor as a scavenger for urokinase‐type plasminogen activator (uPA) , 1994, FEBS letters.

[9]  H. Nekarda,et al.  Tumour-associated proteolytic factors uPA and PAI-1 and survival in totally resected gastric cancer , 1994, The Lancet.

[10]  L. Liotta,et al.  Extracellular matrix 6: Role of matrix metalloproteinases in tumor invasion and metastasis , 1993, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[11]  E. Thiel,et al.  Urokinase-type plasminogen-activator (upa), a protease with cytokine-like activity in human hl-60 leukemic-cell line. , 1993, International journal of oncology.

[12]  Y. Cheng,et al.  Antisense oligonucleotides as therapeutic agents--is the bullet really magical? , 1993, Science.

[13]  A. Levinson,et al.  Prevention of metastasis by inhibition of the urokinase receptor. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[14]  A. Bridges,et al.  Inhibition of urokinase by 4-substituted benzo[b]thiophene-2-carboxamidines: an important new class of selective synthetic urokinase inhibitor. , 1993, Cancer research.

[15]  W. Schleuning,et al.  Interaction of urokinase‐type plasminogenactivator (u‐PA) with its cellular receptor (u‐PAR) induces phosphorylation on tyrosine of a 38 kDa protein , 1993, FEBS letters.

[16]  F. Jänicke,et al.  Saturation of tumour cell surface receptors for urokinase-type plasminogen activator by amino-terminal fragment and subsequent effect on reconstituted basement membranes invasion. , 1993, British Journal of Cancer.

[17]  M. Nerenberg,et al.  Ablation of transplanted HTLV-I tax-transformed tumors in mice by antisense inhibition of NF-kappa B. , 1992, Science.

[18]  R. Kreienberg,et al.  Morphological, immunohistochemical and biochemical characterization of 6 newly established human ovarian carcinoma cell lines , 1992, International journal of cancer.

[19]  M. Kramer,et al.  Generation of cell surface-bound plasmin by cell-associated urokinase-type or secreted tissue-type plasminogen activator: a key event in melanoma cell invasiveness in vitro. , 1992, Experimental cell research.

[20]  A. Maseri,et al.  Age Dependence of Ischaemic Heart Syndromes and the Contribution of Haemostatic Deviations , 1992 .

[21]  M. Nerenberg,et al.  Ablation of transplanted HTLV-I Tax-transformed tumors in mice by antisense inhibition of NF-kappa B. , 1992, Science.

[22]  M. Kramer,et al.  Urokinase-type and tissue-type plasminogen activators are essential for in vitro invasion of human melanoma cells. , 1991, Experimental cell research.

[23]  L. Ossowski,et al.  Inhibition of urokinase-type plasminogen activator by antibodies: the effect on dissemination of a human tumor in the nude mouse. , 1991, Cancer research.

[24]  R. Schultz,et al.  Relationship between secreted urokinase plasminogen activator activity and metastatic potential in murine B16 cells transfected with human urokinase sense and antisense genes. , 1990, Cancer research.

[25]  M. Schmitt,et al.  Role of plasmin in the degradation of the stroma-derived fibrin in human ovarian carcinoma. , 1990, Blood.

[26]  R. Medcalf,et al.  Mouse L cells expressing human prourokinase-type plasminogen activator: effects on extracellular matrix degradation and invasion , 1989, The Journal of cell biology.

[27]  B. Binder,et al.  Growth stimulation of human epidermal cells by urokinase is restricted to the intact active enzyme. , 1989, European journal of biochemistry.

[28]  M. Schmitt,et al.  Fibrin-fibronectin compounds in human ovarian tumor ascites and their possible relation to the tumor stroma. , 1988, Cancer research.

[29]  F. Blasi.  Surface Receptors for Urokinase Plasminogen Activator , 1988 .

[30]  E. Appella,et al.  Modulation of metastatic potential by cell surface urokinase of murine melanoma cells. , 1988, Cancer research.

[31]  J. Plescia,et al.  The plasminogen system and cell surfaces: evidence for plasminogen and urokinase receptors on the same cell type , 1986, The Journal of cell biology.

[32]  D. Rifkin,et al.  Tumor invasion through the human amniotic membrane: Requirement for a proteinase cascade , 1986, Cell.

[33]  K. Danø,et al.  Plasminogen activators, tissue degradation, and cancer. , 1985, Advances in cancer research.

[34]  H. Graeff,et al.  Crosslinked fibrin derivatives and fibronectin in ascitic fluid from patients with ovarian cancer compared to ascitic fluid in liver cirrhosis. , 1984, Thrombosis research.

[35]  L. Ossowski,et al.  Antibodies to plasminogen activator inhibit human tumor metastasis , 1983, Cell.

[36]  L. Holmberg,et al.  Immunological identity of urokinase and ovarian carcinoma plasminogen activator released in tissue culture , 1976, Nature.